- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07704476
EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
14 juli 2026 uppdaterad av: Colin Champ, MD, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
40
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-post: ctgov@ahn.org
Studieorter
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- AHN Allegheny General Hospital
-
Kontakt:
- Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-post: ctgov@ahn.org
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance by a CSCS
- Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Beta blocker or GLP-1 inhibitor medications
- Pregnant women
- Males
- Lactose intolerance
- Cow's milk or whey protein allergy
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: 60 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein.
The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened.
This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate.
Utilizing both will allow individuals with any sensitivity to have increased options.
The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage.
The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).
|
60 grams of whey protein
|
|
Experimentell: 0 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein.
The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened.
This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate.
Utilizing both will allow individuals with any sensitivity to have increased options.
The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage.
The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).
|
0 grams of whey protein
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Determine changes in pounds of muscle and fat mass after each exercise regimen
Tidsram: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
Tidsram: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
Tidsram: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in Y-balance score at the completion of the exercise regimen
Tidsram: Baseline and at program completion (within 4 weeks of exercise completion)
|
Y-Balance score measures the length an individual can extend their foot.
The larger the score the better the balance.
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
Tidsram: Baseline and at program completion (within 4 weeks of exercise completion)
|
FMS measures movement patterns with scoring from 0 to 21.
The large the score the better the mobility.
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Determine changes in phase angle at the completion of the exercise regimen
Tidsram: At program completion (at 8 weeks)
|
Phase angle measures the fluidity of cells and the larger the value the better.
|
At program completion (at 8 weeks)
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Colin Champ, MD, CSCS, AHN Radiation Oncology
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 juni 2026
Primärt slutförande (Beräknad)
1 mars 2027
Avslutad studie (Beräknad)
1 juni 2027
Studieregistreringsdatum
Först inskickad
7 juli 2026
Först inskickad som uppfyllde QC-kriterierna
14 juli 2026
Första postat (Faktisk)
15 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
15 juli 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
14 juli 2026
Senast verifierad
1 juli 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Hudsjukdomar
- Bröstsjukdomar
- Beteende
- Hud- och bindvävssjukdomar
- Neoplasmer
- Bröstneoplasmer
- Motorisk aktivitet
- Aminosyror, peptider och proteiner
- Proteiner
- Mat
- Diet, mat och näring
- Fysiologiska fenomen
- Mat och dryck
- Mejeriprodukter
- Mjölk
- Dietproteiner
- Mjölkproteiner
- Animaliska proteiner, kost
- Vassla
- Vassleproteiner
Andra studie-ID-nummer
- 2026-159-SG
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .